Lumos Pharma

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lumos Pharma excels in Q1 with FDA nod for LUM-201

Lumos Pharma's Q1 2024 earnings call showcased strong performance, financial stability, and promising updates on LUM-201, positioning the company for growth and success in the pharmaceutical industry.
While facing challenges in trial design, enrollment criteria, and funding, Lumos Pharma's innovative approach and positive market reception offer opportunities for market expansion and patient impact.
The call emphasized the potential advantages of LUM-201, the company's robust pipeline, and the importance of securing capital post-FDA trial design approval, setting the stage for future growth and development.

Lumos Pharma progresses LUM-201, seeks strategic partnerships for growth

Lumos Pharma's Q2 2024 performance reflects a strategic focus on advancing LUM-201 and managing costs.
Despite financial challenges and limited cash reserves, the company is leveraging opportunities for growth.
Engagement with Piper Sandler and positive trial data position Lumos Pharma for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 –

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an analysis of interim data from its OraGrowtH212 Trial was given as an oral presentation at the 2023 annual meeting of the European Society for Paediatric Endocrinology (ESPE) , held in The Hague, Netherlands, September 21-23, 2023.

Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting

AUSTIN, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an abstract reviewing interim data from its OraGrowtH212 Trial has been accepted for oral presentation at the 2023 annual meeting of the European Society for Paediatric Endocrinology , to be held in The Hague, Netherlands, September 21-23, 2023.

Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th – 13th and the Cantor Global Healthcare Conference 2023 being held September 26th – 28th in New York City. Lumos Pharma management will present and host one-on-one meetings at both conferences.

Lumos Pharma Announces Participation in Investor Conferences in September

Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time

Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Lisa Miller – Senior Director of Investor Relations Rick Hawkins – Chief Executive Officer and Chairman Lori Lawley – Chief Financial Officer John McKew – President and Chief Scientific Officer Duke Pitukcheewanont – Senior Vice President of Global Clinical Development and Medical Affairs Conference Call Participants Yasmeen Rahimi – Piper Sandler Leland Gershell – Oppenheimer Ed White – H.C. Wainwright Catherine Novack – Jones Trading Pete Stavropoulos – Cantor Fitzgerald Operator Good afternoon, and welcome to Lumos Pharma's Q2 2023 Financial Results Conference Call.

Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript

Lumos Pharma (LUMO) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $0.94 per share a year ago.

Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates

AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, today announced financial results for the second quarter ended June 30, 2023.

Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update

AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its second quarter 2023 financial results after market close on Wednesday, August 9, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023

AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company's President & Chief Scientific Officer, John McKew, PhD, will participate in the Oppenheimer 2023 Life Sciences Summit to be held July 18th – 20t h in Montauk, NY, during which discussions with investors will take place.

Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit

AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that Chief Medical Officer (CMO) Dr. David B. Karpf is departing the company to pursue other opportunities, effective June 29th. Dr. Pisit “Duke” Pitukcheewanont, Lumos Pharma's Senior Vice President, Global Clinical Development and Medical Affairs, along with other members of our clinical team, will oversee all clinical activities and related functions until a CMO search is complete.

Lumos Pharma Announces Departure of Chief Medical Officer

Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, is hosting today a virtual Key Opinion Leader (KOL) Webinar where Drs. Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting, held in Chicago, Illinois, June 15-18, 2023.

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowtH210 and OraGrowtH212 Trials will be reviewed in two oral presentations in Session OR21 – “Update on Growth Disorders” at the 2023 Annual Meeting of the Endocrine Society (ENDO), held in Chicago, Illinois, June 15-18, 2023. Lumos Pharma will host a virtual Key Opinion Leader (KOL) Webinar on June 21, 2023, 11:00 AM – 12 PM EDT where Drs.

Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st

Lumos Pharma (LUMO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $0.92 per share a year ago.

Lumos Pharma (LUMO) Reports Q1 Loss, Tops Revenue Estimates

-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 -- -- Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 – -- Conference Call Scheduled for Today at 4:30pm ET -- AUSTIN, Texas, May 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc . (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, today announced financial results for the quarter ended March 31, 2023.

Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates

Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowtH210 Trial will be reviewed in an oral presentation at the 2023 Annual Meeting of the Pediatric Endocrine Society (PES), held in San Diego, California, May 5-8, 2023. Data from the interim analysis of its OraGrowtH212 Trial are also being presented as a poster during the medical meeting.

Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)

AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis

Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman Lori Lawley - CFO & Principal Accounting Officer John McKew - Chief Scientific Officer & President David Karpf - Chief Medical Officer Conference Call Participants Peter Rosenthal - Cantor Catherine Novack - Jones Trading Eun Yang - Jefferies Ed White - H.C. Wainwright & Co. Operator Good afternoon, and welcome to Lumos Pharma's 2022 Financial Results Conference Call.

Lumos Pharma, Inc. (LUMO) Q4 2022 Earnings Call Transcript

Lumos (LUMO) delivered earnings and revenue surprises of -3.16% and 48.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Lumos Pharma (LUMO) Reports Q4 Loss, Tops Revenue Estimates

-- Patient Enrollment Completed in OraGrowtH210 and OraGrowtH212 Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected Q4 2023 --

Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates

Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled

Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD

AUSTIN, Texas, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2022 financial results after market close on Wednesday, March 1, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023

AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 12th Annual LifeSci Partners Corporate Access Event held in San Francisco January 9-11, 2023. Lumos Pharma will host in-person one-on-one meetings with the investment and biopharmaceutical community on Tuesday and Wednesday, January 10th and 11th, during the event.

News for Lumos Pharma Stock (LUMO)